Test filters

News

In the media

Press releases

Publications

Scientific articles

Statements

Stories

Videos

Viewpoints

In the media

18 Dec 2025

The motorcyclist fighting a deadly disease in the African bush

BBC

Scientific articles

17 Dec 2025

Kronopolitides A–F, a family of 36-membered polyol macrolides with antiparasitic activity against Chagas disease

Journal of Natural Products

News

16 Dec 2025

DNDi 2025 in Review

In the media

15 Dec 2025

The biggest mosquito-borne disease in the world has a cure. There’s just one problem

Vox

In the media

10 Dec 2025

Explainer: Chagas disease spreads to richer countries

Financial Times

News

8 Dec 2025

DNDi statement on COP30: Advancing health in the climate agenda

News

4 Dec 2025

Dr Javid Abdelmoneim, Datuk Dr Mahathar bin Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira join the Board of Directors at DNDi

In the media

2 Dec 2025

“Como si me comiera desde dentro”: la enfermedad que ataca los huesos en el norte de Kenia

EFE

Scientific articles

2 Dec 2025

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

Parasites & Vectors

Press releases

27 Nov 2025

International seminar explores the development of treatments for dengue for populations not covered by vaccines

News

26 Nov 2025

DNDi statement on the approval of the Instituto Butantan’s dengue vaccine and the need for a dengue treatment

Scientific articles

25 Nov 2025

Bidirectional interaction between liposomal amphotericin B pharmacokinetics and parasite dynamics in patients with post-kala-azar dermal leishmaniasis: Potential implications for optimal dosing

Clinical Pharmacology & Therapeutics

Videos

24 Nov 2025

Interview with Dr Pauline Williams, new DNDi Scientific Advisory Committee (SAC) Chair

Scientific articles

20 Nov 2025

Leishmaniasis

Nature Reviews Disease Primers

Scientific articles

20 Nov 2025

Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology

Viewpoints

20 Nov 2025

Neglecting infectious diseases is a market failure

Financial Times

International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

The motorcyclist fighting a deadly disease in the African bush

Kronopolitides A–F, a family of 36-membered polyol macrolides with antiparasitic activity against Chagas disease

DNDi 2025 in Review

The biggest mosquito-borne disease in the world has a cure. There’s just one problem

Explainer: Chagas disease spreads to richer countries

DNDi statement on COP30: Advancing health in the climate agenda

Dr Javid Abdelmoneim, Datuk Dr Mahathar bin Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira join the Board of Directors at DNDi

“Como si me comiera desde dentro”: la enfermedad que ataca los huesos en el norte de Kenia

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

International seminar explores the development of treatments for dengue for populations not covered by vaccines

DNDi statement on the approval of the Instituto Butantan’s dengue vaccine and the need for a dengue treatment

Bidirectional interaction between liposomal amphotericin B pharmacokinetics and parasite dynamics in patients with post-kala-azar dermal leishmaniasis: Potential implications for optimal dosing

Interview with Dr Pauline Williams, new DNDi Scientific Advisory Committee (SAC) Chair

Leishmaniasis

Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

Neglecting infectious diseases is a market failure

Learn more

Get in touch

Support us

Work with us